UNSPSC 51281631: Viomycin

This classification denotes an antitubercular agent with the molecular formula C25H43N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, YVU35998K5 chemically known as glycine, 3-amino-n-((3s)-3,6-diamino-1-oxohexyl)-l-alanyl-l-seryl-l-seryl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-2-((4r,6s)-2-amino-1,4,5,6-tetrahydro-6-hydroxy-4-pyrimidinyl)-, (5->13)-lactam, (2s)- but generally known as viomycin, which bears US NIH Compound Identifier 3032902.

UNSPSC 51281631 Viomycin, a Commodity code, nominally addresses a specific antibiotic but does not align with the recent state and local opportunities actually posted under this classification. The most recent solicitations tagged to this code seek naloxone and drug deactivation systems, generic pharmaceuticals and OTC products through cooperative purchasing, and medical and first aid supplies for emergency response — none of which involve viomycin procurement. The code shows a significant mismatch between its nominal scope and actual buying activity, rendering it an unreliable signal for viomycin-related opportunities.

Recent activity under the code reflects pharmaceutical and medical supply procurement across diverse issuing bodies: Seminole County, Florida (health and human services); the City of Tampa (emergency response); the Texas Health and Human Services Commission (pharmacy benefits); and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state cooperative for generic drugs and OTC products serving participating state and local facilities). The geographic spread includes Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) requesting 1,900 units annually for quarterly delivery; the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (posted March 25, 2026, due March 13, 2026, estimated contract value $700,000) as a sheltered Small Local Business Enterprise opportunity with a 5 percent bid discount; MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) requiring vendors to supply through authorized wholesalers with products available by May 15, 2026; and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026, due April 3, 2026) seeking vendor capabilities for therapeutic pharmacy initiatives. This code does not reliably surface viomycin procurement opportunities and should be monitored only if your firm specializes in broader pharmaceutical or emergency medical supply distribution to state and local health agencies.